A Research Study for Patients With Prostate Cancer
This study has been completed.
Information provided by (Responsible Party):
First received: March 24, 2005
Last updated: September 12, 2014
Last verified: September 2014
The purpose of this study is to evaluate the activity of romidepsin (depsipeptide,FK228) in patients with metastatic prostate cancer who have developed a rising prostate specific antigen (PSA) while undergoing hormonal therapy.
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
||An Exploratory Phase II, Multicenter, Open-label Trial Evaluating the Activity and Tolerability of FK228 in Androgen Independent Metastatic Prostate Cancer Patients With Rising PSA
Primary Outcome Measures:
- Rate of objective disease control [ Time Frame: Up to 6 months ] [ Designated as safety issue: No ]
Rate of objective disease control was defined as the proportion of patients with confirmed CR, PR, or SD for at least 6 months, as determined by the Response Evaluation Criteria for Solid Tumors (RECIST).
| Study Start Date:
| Study Completion Date:
| Primary Completion Date:
||September 2006 (Final data collection date for primary outcome measure)
13 mg/m^2 of romidepsin intravenously over 4 hours on Days 1, 8, and 15 of each 28-day cycle.
13 mg/m2 of romidepsin intravenously over 4 hours on Days 1, 8, and 15 of each 28-day cycle.
- FK 228
|Ages Eligible for Study:
||18 Years and older
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
- Males ≥18 years;
- Written informed consent/authorization;
- Histological or cytological confirmation of metastatic prostate cancer with documented progression on hormonal therapy (objective progressive disease [PD], new bone lesions, or stable soft tissue or bone lesions with PSA increase);
- Patients must have either measurable disease or bone metastasis. Patients with measurable disease are preferred;
- Rising PSA, with a minimum study entry PSA of ≥5 ng/mL;
- Karnofsky performance status of ≥80%;
- Life expectancy of >12 weeks;
- For patients treated with anti-androgens, elevation of PSA must be demonstrated after cessation of anti-androgen treatment;
- Three lines of hormonal therapy are permitted prior to study entry (anti-androgen withdrawal is not considered as a second hormonal treatment);
- Serum testosterone level of <50 ng/mL in patients without surgical castration;
- Patients must have serum potassium levels >4.0 mEq/L and serum magnesium levels >2.0 mg/dL.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
No Contacts or Locations Provided
No publications provided
History of Changes
|Other Study ID Numbers:
|Study First Received:
||March 24, 2005
||September 12, 2014
||United States: Food and Drug Administration
Keywords provided by Celgene Corporation:
Androgen independent metastatic prostate cancer patients with rising PSA
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on October 19, 2014
Genital Neoplasms, Male
Neoplasms by Site
Genital Diseases, Male